Loading…
Loading…
INCY does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for INCY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for INCY and 80,000+ other tickers.
See exactly how INCY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for INCY and 80,000+ other tickers.
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among…
Bank of New York Mellon Corp lessened its holdings in Incyte Corporation (NASDAQ: INCY) by 1.3% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 989,709 shares of the biopharmaceutical company's stock after selling 12,540 shares during the period. Bank of New York
Fifth Third Bancorp boosted its stake in shares of Incyte Corporation (NASDAQ: INCY) by 145.2% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm owned 27,289 shares of the biopharmaceutical company's stock after buying an additional 16,160 shares during the quarter. Fifth Third Bancorp's
Andra AP fonden lessened its position in Incyte Corporation (NASDAQ: INCY) by 34.6% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 259,048 shares of the biopharmaceutical company's stock after selling 137,252 shares during the quarter. Andra AP fonden owned about 0.13%
Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option to nominate up to two additional targets SAN DIEGO, July 20, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has entered into a global collaboration and license agreement with Incyte (Nasdaq: INCY) to evaluate additional subcutaneous formulations of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs), utilizing Halozyme's proprietary ENHANZE® drug delivery technology. The collaboration will focus on the potential for ENHANZE® to strengthen the subcutaneous formulation currently in development for INCA033989, with the goal of enabling more convenient delivery and dosing regimens that may improve the treatment experience.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Data to Be Highlighted in Four Rapid Oral Presentations at ESMO 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers.